drugset / Trial / NCT01660633
Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation
Phase 2
Completed
61 enrolled
Acrotech Biopharma Inc.
Beckloff Associates, Inc. · collabClinipace Worldwide · collabKansas City Bioanalytical Laboratories · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this trial is to confirm the safety and efficacy of high-dose Melphalan HCL for Injection (Propylene Glycol-Free) as a myeloablative conditioning regimen in multiple myeloma patients (MM) undergoing autologous transplantation.
Timeline
- Start
- 2012-12
- Primary completion
- 2014-02
- Completion
- 2014-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Melphalan | Small molecule | 100 mg/m2 | Intravenous |